Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innate PharmaIPHA -1.41%41 EV-to-OCF is -4.02 as of Jul. 18, 2026. GuruFocus rates IPHA with a GF Score™ of 41/100 and a GF Value™ of $0.16 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,411 Biotechnology companies, Innate Pharma ranks better than 53.58% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Innate Pharma's Enterprise Value is $150.90 Mil.
Innate Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-37.58 Mil. Therefore, Innate Pharma's EV-to-OCF for today is -4.02.
The historical rank and industry rank for Innate Pharma's EV-to-OCF or its related term are showing as below:
IPHA'
s EV-to-OCF Range Over the Past 10 Years
Min: -18.64 Med: -3.84 Max: 7.95
Current: -3.99
During the past 13 years, the highest EV-to-OCF of Innate Pharma was 7.95. The lowest was -18.64. And the median was -3.84.
IPHA's EV-to-OCF is ranked better than 53.58% of 1411
companies
in the Biotechnology industry
Industry Median: -3.28
vs IPHA: -3.99
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Innate Pharma's PE Ratio (TTM) for today is calculated as:
Innate Pharma's share price for today is $1.75.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innate Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.639.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Innate Pharma EV-to-OCF Related Terms
Innate Pharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Innate Pharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Innate Pharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innate Pharma EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innate Pharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Innate Pharma's EV-to-OCF falls into.
Innate Pharma's current Enterprise Value is $150.90 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innate Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-37.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innate Pharma (IPHA) has a EV-to-OCF of -4.02 as of Jul. 18, 2026. According to the industry distribution chart, Innate Pharma ranks #655 out of 1411 companies in the Biotechnology industry, placing it in the top 46.4%.
Is Innate Pharma's EV-to-OCF too high?
Innate Pharma's current EV-to-OCF is -4.02. Based on the distribution chart, Innate Pharma ranks #655 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Innate Pharma has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innate Pharma's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innate Pharma ranks #655 out of 1411 companies for EV-to-OCF. This puts Innate Pharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Innate Pharma's current EV-to-OCF is -4.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innate Pharma stock overvalued right now?
Based on GuruFocus' analysis, Innate Pharma (IPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $1.75 — trading 993.8% above its estimated fair value. The current EV-to-OCF is -4.02. Innate Pharma's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Innate Pharma (IPHA), the current EV-to-OCF is -4.02 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innate Pharma (IPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued.
The current stock price of $1.75 is trading 993.8% above its estimated GF Value™ of $0.16.
GuruFocus considers Innate Pharma to be Significantly Overvalued.
Key valuation signals for IPHA:
EV-to-OCF: -4.02
GF Value™: $0.16 vs. price of $1.75 (993.8% above fair value)
No single metric tells the full story. See the IPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
41GF Score
Get the complete analysis for IPHA
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPHA has been successfully added to your 
